KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Inventory (2016 - 2026)

Bio-Rad Laboratories has reported Inventory over the past 18 years, most recently at $770.5 million for Q1 2026.

  • Quarterly Inventory fell 2.48% to $770.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $770.5 million through Mar 2026, down 2.48% year-over-year, with the annual reading at $740.7 million for FY2025, 2.54% down from the prior year.
  • Inventory was $770.5 million for Q1 2026 at Bio-Rad Laboratories, up from $740.7 million in the prior quarter.
  • Over five years, Inventory peaked at $804.3 million in Q3 2024 and troughed at $605.5 million in Q1 2022.
  • The 5-year median for Inventory is $775.8 million (2023), against an average of $752.3 million.
  • Year-over-year, Inventory grew 25.7% in 2022 and then fell 2.63% in 2024.
  • A 5-year view of Inventory shows it stood at $719.3 million in 2022, then grew by 8.51% to $780.5 million in 2023, then dropped by 2.63% to $760.0 million in 2024, then dropped by 2.54% to $740.7 million in 2025, then increased by 4.02% to $770.5 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Inventory are $770.5 million (Q1 2026), $740.7 million (Q4 2025), and $783.2 million (Q3 2025).